A single blood draw that screens for dozens of cancers at once is moving closer to reality. The Food and Drug Administration is reviewing one such test and could approve it before the end of the year. If that happens, the way doctors screen for cancer could start to look very different.
How the Test Works
Most cancer screening today targets one disease at a time. In the United States, routine programs typically cover five cancers, each with its own scan or exam, from mammograms to colonoscopies:
- Breast
- Colon
- Cervical
- Prostate
- Lung
A multi-cancer blood test takes a different approach. It looks for small fragments of DNA and other markers that tumors shed into the bloodstream. One test under FDA review, called Galleri, can screen for signals tied to as many as 50 cancers from a single vial of blood.
A competing test, Cancerguard, works on a similar principle. Both can already be ordered in limited circumstances, though fuller FDA approval would open the door to wider use.
These tests fall under a category known as multi-cancer early detection. The American Cancer Society explains how MCED tests work for patients weighing their options.
What It Can and Cannot Do
A multi-cancer blood test does not diagnose cancer. It flags the likely presence and possible source of a cancer signal, then points doctors toward where to look next.
A positive result still requires follow-up. That might mean imaging, a biopsy, or other standard tests to confirm whether cancer is actually present.
Doctors also stress that these tests are meant to add to current screening, not replace it. The goal is to catch more cancers earlier, especially the many types that have no routine screening at all today.
The Cost and Coverage Question
Price remains a real barrier. According to NPR’s reporting, Galleri carries a retail price of $950, while Cancerguard runs $659. Neither is widely covered by insurance yet.
That could change. As part of a spending package passed in February, Congress cleared a path for Medicare to reimburse multi-cancer detection tests starting in 2028, once the FDA grants fuller approval. How private insurers will price coverage is still unknown.
What the Research Shows
The evidence so far is encouraging but mixed. Grail, the company behind Galleri, ran two large studies in people over 50, including one through the United Kingdom’s National Health Service with more than 142,000 participants.
That study did not hit its main goal of significantly reducing later-stage cancers over time. Still, when the company combined results from both studies, it reported a promising trend, including a 26% drop in Stage IV cases during the third year for several aggressive cancers such as pancreatic, liver, and lung.
Why does staging matter so much? Catching a cancer at Stage 3 rather than Stage 4 can change a patient’s odds considerably, especially as treatments for earlier-stage disease keep improving.
What Comes Next
FDA approval is not guaranteed, and the timeline could shift. Researchers also caution that the technology is still developing. The longer-term hope is for tests sensitive enough to flag risk even earlier, though that capability does not exist yet.
For readers who follow health news, this is a development worth watching, since broader access could reshape routine checkups for millions of people.
If you are considering any cancer screening, talk with your doctor about what fits your age, history, and personal risk. For continued coverage of medical advances and the policies behind them, Aloha News Network continues to cover the breakthroughs and policy decisions that affect patients.